PMID- 37668154
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 22
IP  - 10
DP  - 2023 Jul-Dec
TI  - Safety of PARP inhibitors as maintenance therapy in ovarian cancer.
PG  - 897-908
LID - 10.1080/14740338.2023.2254699 [doi]
AB  - INTRODUCTION: Antiangiogenic agents and poly(ADP-ribose) polymerase inhibitors 
      (PARP-Is) have improved the outcome of patients suffering from ovarian cancer. 
      However, as they are associated with many adverse events (AEs), it is important 
      to be aware of their safety and toxicity profiles. AREAS COVERED: We reviewed 
      PARP-I therapeutical indications, mechanism of action, metabolism, and 
      interactions. We reported on all major and minor AEs that have emerged from 
      clinical trials (SOLO1, PRIMA, PAOLA1, ATHENA, SOLO2, NOVA, ARIEL3, NORA), their 
      follow-ups, meta-analyses, and real-world studies, particularly hematologic 
      toxicities and their management, and secondary malignancies (myelodysplastic 
      syndrome and acute myeloid leukemia). We also addressed gastrointestinal, 
      neurological, respiratory, hepatic, and renal toxicity and the use of PARP-Is in 
      older, pregnant, and lactating patients. No specific research strategy in terms 
      of keywords, inclusive dates and databases was used. EXPERT OPINION: PARP-Is 
      benefits largely outweigh the risks associated with potential AEs. Randomized 
      controlled trials produced strong good, quality data, but they enrolled a 
      selected population and failed to capture rare events. More pharmacovigilance 
      data and real-life studies on a larger and more heterogeneous sample are needed 
      to understand PARP-Is differences and to clarify the incidence of late AEs to 
      balance the risk/benefit ratio.
FAU - Cecere, Sabrina Chiara
AU  - Cecere SC
AD  - Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 
      G. Pascale, Naples, Italy.
FAU - Casartelli, Chiara
AU  - Casartelli C
AD  - Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
FAU - Forte, Miriam
AU  - Forte M
AD  - Department of Precision Medicine, Division of Medical Oncology, University of 
      Campania Luigi Vanvitelli, Naples, Italy.
FAU - Pignata, Sandro
AU  - Pignata S
AD  - Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 
      G. Pascale, Naples, Italy.
FAU - Pisano, Carmela
AU  - Pisano C
AD  - Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 
      G. Pascale, Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230914
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Piperidines)
SB  - IM
MH  - Humans
MH  - Female
MH  - Aged
MH  - *Poly(ADP-ribose) Polymerase Inhibitors/adverse effects
MH  - Lactation
MH  - *Ovarian Neoplasms/drug therapy
MH  - Piperazines
MH  - Piperidines/adverse effects
OTO - NOTNLM
OT  - PARP inhibitor
OT  - acute myeloid leukemia
OT  - adverse events
OT  - myelodysplastic syndrome
OT  - niraparib
OT  - olaparib
OT  - ovarian cancer
OT  - rucaparib
EDAT- 2023/09/05 12:42
MHDA- 2023/09/05 12:43
CRDT- 2023/09/05 06:53
PHST- 2023/09/05 12:43 [medline]
PHST- 2023/09/05 12:42 [pubmed]
PHST- 2023/09/05 06:53 [entrez]
AID - 10.1080/14740338.2023.2254699 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2023 Jul-Dec;22(10):897-908. doi: 
      10.1080/14740338.2023.2254699. Epub 2023 Sep 14.